Loading...
Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
Wiechno, P Alekseev, B Sala, N Jones, R Kocak, I Chiuri, V Jassem, J Fléchon, A Redfern, C
Wiechno, P
Alekseev, B
Sala, N
Jones, R
Kocak, I
Chiuri, V
Jassem, J
Fléchon, A
Redfern, C
Citations
Altmetric:
Abstract
Patients with metastatic castration-resistant prostate cancer and homologous recombination repair (HRR) mutations have a better response to treatment with the poly(ADP-ribose) polymerase inhibitor olaparib than patients without HRR mutations. Preclinical data suggest synergy between olaparib and androgen pathway inhibitors. We aimed to assess the efficacy of olaparib plus the androgen pathway inhibitor abiraterone in patients with metastatic castration-resistant prostate cancer regardless of HRR mutation status.
Description
Date
2018-06-04
Publisher
Collections
Keywords
Type
Article
Citation
Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. 2018, Lancet Oncol